絞り込み

17410

広告

Association Between Secondary Botulinum Toxin A Treatment Failure in Cosmetic Indication and Anti-Complexing Protein Antibody Production.

著者 Wanitphakdeedecha R , Kantaviro W , Suphatsathienkul P , Tantrapornpong P , Yan C , Apinumtham C , Srinoulprasert Y
Dermatol Ther (Heidelb).2020 May 22 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (1view , 0users)

Full Text Sources

Botulinum toxin A (BoT/A) treatment failure (BTF) affects patients subjected to repeated BoT/A exposure for cosmetic indications. BoT/A's general formulation contains core BoT/A and complexing proteins. BTF may be caused by antibody-induced treatment failure. Antibodies against core BoT/A can occur; however, anti-complexing protein antibodies have never been demonstrated, and tools for anti-complexing protein antibody detection have not been developed. The aim of this study was to evaluate immune involvement in BoT/A-nonresponsive patients.
PMID: 32445175 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード